FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
Approval based on noninferior pharmacokinetic exposures, similar effectiveness and safety to intravenous Opdivo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.